To include your compound in the COVID-19 Resource Center, submit it here.

Nimotuzumab: Phase III discontinued

In April, Daiichi Sankyo discontinued a double-blind, placebo-controlled, Japanese Phase III trial evaluating IV nimotuzumab with concurrent chemoradiotherapy as first-line treatment of unresectable and locally advanced squamous cell lung

Read the full 291 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE